WO2005016260A3 - Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides - Google Patents

Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides Download PDF

Info

Publication number
WO2005016260A3
WO2005016260A3 PCT/US2004/024109 US2004024109W WO2005016260A3 WO 2005016260 A3 WO2005016260 A3 WO 2005016260A3 US 2004024109 W US2004024109 W US 2004024109W WO 2005016260 A3 WO2005016260 A3 WO 2005016260A3
Authority
WO
WIPO (PCT)
Prior art keywords
amine
peptides
oral
amino acids
prodrugs
Prior art date
Application number
PCT/US2004/024109
Other languages
French (fr)
Other versions
WO2005016260A2 (en
Inventor
Kelvin W Gee
Jinghua J Wang
Derk J Hogenkamp
Original Assignee
Univ California
Kelvin W Gee
Jinghua J Wang
Derk J Hogenkamp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Kelvin W Gee, Jinghua J Wang, Derk J Hogenkamp filed Critical Univ California
Publication of WO2005016260A2 publication Critical patent/WO2005016260A2/en
Publication of WO2005016260A3 publication Critical patent/WO2005016260A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Abstract

Compounds and compositions for prodrugs useful for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides are described. Compounds containing biologically-active amino groups are conjugated to a lipophilic derivative through an amide bond in order to facilitate transport of the conjugate through the cell membrane. Methods of coupling a biologically-active molecule containing at least one amine functional group to a lipophilic anhydride are also described.
PCT/US2004/024109 2003-08-08 2004-07-26 Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides WO2005016260A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49393803P 2003-08-08 2003-08-08
US60/493,938 2003-08-08

Publications (2)

Publication Number Publication Date
WO2005016260A2 WO2005016260A2 (en) 2005-02-24
WO2005016260A3 true WO2005016260A3 (en) 2005-10-20

Family

ID=34193194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024109 WO2005016260A2 (en) 2003-08-08 2004-07-26 Prodrugs for the oral and parenteral delivery of amine-containing drugs, amino acids, and peptides

Country Status (1)

Country Link
WO (1) WO2005016260A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US20040167287A1 (en) * 2002-12-31 2004-08-26 Antoni Kozlowski Maleamic acid polymer derivatives and their bioconjugates

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
US20040167287A1 (en) * 2002-12-31 2004-08-26 Antoni Kozlowski Maleamic acid polymer derivatives and their bioconjugates

Also Published As

Publication number Publication date
WO2005016260A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
EP1881020A4 (en) Polymeric derivative of cytidine metabolic antagonist
WO2007030573A3 (en) Polypeptides useful for molecular weight determinations
BRPI0506864A (en) method for conjugating peptides, conjugated peptide, compound and pharmaceutically acceptable salts, prodrugs and solvates thereof, pharmaceutical composition, use of a compound, and method for treating disease
GB0716897D0 (en) Cancer imaging and treatment
ES2834916T3 (en) Polylysine dendrimer targeted therapeutic agent
WO2006016168A3 (en) Sialic acid derivatives
WO2006029411A3 (en) Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
BR0013577A (en) Dipeptidyl peptidase iv effectors for topical use
WO2008039483A3 (en) Modified self-assembling peptides
WO2007096662A3 (en) Cancer imaging and treatment
WO2003026577A3 (en) P-amidobenzylethers in drug delivery agents
WO2000052015A3 (en) Novel phosphorus-containing prodrugs
WO2008069824A3 (en) Compositions and methods for transport of molecules with enhanced release properties across biological barriers
JP2016508136A5 (en)
WO2006136586A3 (en) N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs
WO2006101782A3 (en) A cysteine-containing peptide tag for site-specific conjugation of proteins
GB0012850D0 (en) Cyclic amino acid derivatives useful as pharmaceutical agents
WO2005104648A3 (en) Pegylated nanoparticles
CA2413629A1 (en) Solid method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity
WO2007120648A2 (en) Mono and di-substituted oxycodone compounds and compositions
WO2006014429A3 (en) Cidofovir peptide conjugates as prodrugs
CA2246227A1 (en) Composition for the transfection of higher eucaryotic cells
WO2003057164A3 (en) Compounds for delivering substances into cells
WO2003035011A3 (en) Multidrug multiligand conjugates for targeted drug delivery

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase